<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lichen planus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lichen planus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lichen planus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eliot Mostow, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lichen planus is an uncommon disorder of unknown cause that most commonly affects middle-aged adults. Lichen planus may affect the skin (cutaneous lichen planus), oral cavity (oral lichen planus), genitalia (penile or vulvar lichen planus), scalp (lichen planopilaris), nails, or esophagus.</p><p>The diagnosis and management of lichen planus, with a focus on cutaneous lichen planus, will be reviewed here. Oral lichen planus, vulvar lichen planus, lichen planopilaris, nail lichen planus, and lichenoid drug eruption (drug-induced lichen planus) are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">"Oral lichen planus: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris"</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a> and  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)"</a>.)</p><p class="headingAnchor" id="H511769"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The epidemiology of lichen planus is not well defined. Based upon limited data, cutaneous lichen planus is estimated to occur in less than 1 percent of the population<sup> </sup>[<a href="#rid1">1</a>].</p><p>Cutaneous lichen planus most frequently develops between the ages of 30 and 60 years [<a href="#rid1">1-3</a>]. Childhood cutaneous lichen planus occurs, but is uncommon [<a href="#rid4">4</a>]. There does not appear to be a strong sex or racial predilection for cutaneous lichen planus [<a href="#rid1">1,2</a>].</p><p>Epidemiologic data on other forms of lichen planus are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of lichen planus is not known. An immune-mediated mechanism involving activated T cells, particularly CD8+ T cells, directed against basal keratinocytes has been proposed [<a href="#rid5">5</a>]. Upregulation of intercellular adhesion molecule-1 (ICAM-1) and cytokines associated with a Th1 immune response, such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 alpha, IL-6, and IL-8, may also play a role in the pathogenesis of lichen planus [<a href="#rid5">5-8</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Hepatitis C virus</span><span class="headingEndMark"> — </span>The association of hepatitis C virus (HCV) with lichen planus is controversial, and a cause and effect relationship is uncertain. A meta-analysis of primarily case-control studies conducted in a number of countries found a statistically significant association between HCV and lichen planus. Compared with control patients, the prevalence of HCV exposure was greater among patients with lichen planus (OR 5.4, 95% CI 3.5-8.3) [<a href="#rid9">9</a>]. A systematic review also identified an increase in the proportion of lichen planus patients that were HCV positive compared with controls (OR 4.80, 95% CI 3.25-7.09) [<a href="#rid10">10</a>]. However, subgroup analysis in both studies revealed that the strength of this association varied geographically, and was not statistically significant in all locations. Estimates of the prevalence of HCV infection among patients with oral lichen planus vary widely; studies have reported prevalence rates from 0 to 62 percent [<a href="#rid11">11</a>].</p><p>Clinicians should have a high suspicion for lichen planus in patients with hepatitis C who present with clinical features suggestive of the diagnosis. The meta-analysis cited above found that patients with HCV had an increased prevalence of lichen planus compared to controls (OR 2.5, 95% CI, 2.0-3.1) [<a href="#rid9">9</a>]. In a study from Italy, among 178 adults with HCV antibodies, five (2.8 percent) had oral lichen planus [<a href="#rid12">12</a>]. There are also reports of the development or exacerbation of lichen planus during interferon treatment for chronic HCV; the lesions improved when interferon was stopped [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H512164"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Clinical manifestations that resemble idiopathic lichen planus can occur as a result of drug exposure  (<a class="graphic graphic_table graphicRef83762" href="/z/d/graphic/83762.html" rel="external">table 1</a>). Lichenoid drug eruptions (also known as drug-induced lichen planus) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Lichen planus may affect the skin, mucous membranes (especially the oral mucosa), scalp, nails, and genitalia [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H512025"><span class="h2">Cutaneous lichen planus</span><span class="headingEndMark"> — </span>The classic presentation of cutaneous lichen planus is a papulosquamous eruption characterized by the development of flat-topped, violaceous papules on the skin  (<a class="graphic graphic_picture graphicRef63590 graphicRef76383 graphicRef50579 graphicRef53839" href="/z/d/graphic/63590.html" rel="external">picture 1A-D</a>). Often, the clinical manifestations are described as the four "P's":</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritic </p><p class="bulletIndent1"><span class="glyph">●</span>Purple (actually a slight violaceous hue)</p><p class="bulletIndent1"><span class="glyph">●</span>Polygonal</p><p class="bulletIndent1"><span class="glyph">●</span>Papules or plaques</p><p></p><p>Individual papules are usually a few millimeters in diameter, but may coalesce to form larger plaques [<a href="#rid2">2</a>]. With close inspection, fine white lines may be visible on the surface of papules or plaques of cutaneous lichen planus  (<a class="graphic graphic_picture graphicRef61523" href="/z/d/graphic/61523.html" rel="external">picture 2</a>). These lines are described by the term "Wickham's striae" [<a href="#rid14">14</a>].</p><p>The extremities, particularly the ankles and the volar surface of the wrists, are common sites for cutaneous involvement [<a href="#rid5">5</a>]. Involvement of the trunk or generalized involvement also can occur  (<a class="graphic graphic_picture graphicRef50632" href="/z/d/graphic/50632.html" rel="external">picture 3</a>). Rare Blaschkoid  (<a class="graphic graphic_picture graphicRef89626" href="/z/d/graphic/89626.html" rel="external">picture 4</a> and <a class="graphic graphic_figure graphicRef57219" href="/z/d/graphic/57219.html" rel="external">figure 1</a>) [<a href="#rid15">15-17</a>], zosteriform [<a href="#rid18">18-21</a>], and inverse (intertriginous) [<a href="#rid2">2</a>] distributions of cutaneous lichen planus have been observed.</p><p>Patients with lichen planus may exhibit the Koebner reaction (the development of skin lesions in sites of trauma). The Koebner reaction most often occurs as a result of scratching  (<a class="graphic graphic_picture graphicRef68060" href="/z/d/graphic/68060.html" rel="external">picture 5</a>). </p><p>The pruritus associated with cutaneous lichen planus often is intense. Asymptomatic eruptions are rare. Lesions often heal with significant postinflammatory hyperpigmentation.</p><p class="headingAnchor" id="H512249"><span class="h3">Cutaneous variants</span><span class="headingEndMark"> — </span>In addition to the classic presentation of cutaneous lichen planus, multiple other clinical presentations of cutaneous disease have been described. Shared histologic findings support the classification of these disorders as variants of cutaneous lichen planus.</p><p>Examples of variants of cutaneous lichen planus include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic lichen planus </strong>– Hypertrophic lichen planus is characterized by the development of intensely pruritic, flat-topped plaques  (<a class="graphic graphic_picture graphicRef54396" href="/z/d/graphic/54396.html" rel="external">picture 6</a>). The typical site of involvement is the anterior lower legs. Of note, the occasional development of cutaneous squamous cell carcinoma has been reported in patients with longstanding hypertrophic lichen planus lesions [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Annular lichen planus </strong>– Annular lichen planus is characterized by the development of violaceous plaques with central clearing  (<a class="graphic graphic_picture graphicRef53806 graphicRef76913 graphicRef68197" href="/z/d/graphic/53806.html" rel="external">picture 7A-C</a>). Although the penis, scrotum, and intertriginous areas are common sites of involvement, annular lesions may occur in other areas [<a href="#rid23">23</a>]. Central atrophy may be present. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous lichen planus </strong>– Patients with bullous lichen planus develop vesicles or bullae within the sites of existing cutaneous lichen planus lesions. The legs are a common site of lesion development [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Actinic lichen planus </strong>– Actinic lichen planus (also known as lichen planus tropicus) presents with a photodistributed eruption of hyperpigmented macules, annular papules, or plaques [<a href="#rid2">2</a>]. This variant is most commonly seen in the Middle East, India, and east Africa [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus pigmentosus </strong>– Lichen planus pigmentosus presents with gray-brown or dark brown macules or patches that are most commonly found in sun-exposed or flexural areas [<a href="#rid24">24</a>]. Pruritus is minimal or absent. The term "lichen planus pigmentosus-inversus" is used to describe patients with primarily flexural involvement [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inverse lichen planus </strong>– Inverse lichen planus is characterized by erythematous to violaceous papules and plaques in intertriginous sites, such as the axillae, inguinal creases, inframammary area, or limb flexures  (<a class="graphic graphic_picture graphicRef90122" href="/z/d/graphic/90122.html" rel="external">picture 8</a>) [<a href="#rid2">2</a>]. Associated hyperpigmentation is common. Scale and erosions may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrophic lichen planus </strong>– Atrophic lichen planus presents with violaceous, round or oval, atrophic plaques. The legs are a common site of involvement [<a href="#rid2">2</a>], and lesions often clinically resemble extragenital lichen sclerosus. A rare annular atrophic variant of lichen planus characterized by violaceous papules that enlarge peripherally leaving an atrophic center that demonstrates complete loss of elastic fibers on pathology has also been reported [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planopilaris (follicular lichen planus) </strong>– The scalp is the classic site for lichen planopilaris. However, follicular involvement manifesting as follicular papules may be observed in other body sites, particularly in patients with the Graham-Little-Piccardi-Lasseur syndrome. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Introduction'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Graham-Little-Piccardi-Lasseur syndrome'</a>.)</p><p></p><p>Additional variants include palmoplantar lichen planus (a variant that may demonstrate ulceration) [<a href="#rid29">29-31</a>] and perforating [<a href="#rid32">32,33</a>] lichen planus. </p><p class="headingAnchor" id="H97421250"><span class="h2">Overlap syndromes</span><span class="headingEndMark"> — </span>Lichen planus pemphigoides and lichen planus-lupus erythematous overlap syndrome are disorders that are characterized by the presence of features of cutaneous lichen planus and a second disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus pemphigoides </strong>–<strong> </strong>Lichen planus pemphigoides presents with overlapping features of lichen planus and bullous pemphigoid. The onset of lichen planus usually precedes the onset of bullous lesions [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Patients develop bullae in sites of previously normal appearing skin and on top of lesions of lichen planus [<a href="#rid34">34</a>]. This contrasts with bullous lichen planus, which presents with bullae that are limited to longstanding lichen planus lesions. Similar to bullous pemphigoid, direct immunofluorescence studies of lichen planus pemphigoides demonstrate linear deposition of IgG and C3 at the dermal-epidermal junction. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Direct immunofluorescence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus-lupus erythematosus overlap syndrome </strong>–<strong> </strong>The term "lichen planus-lupus erythematous overlap syndrome" refers to a rare condition in which patients develop skin lesions with clinical, histologic, and/or immunopathologic features of both diseases. Clinically, patients often present with blue-red atrophic plaques or upper extremity verrucous papules or nodules [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H512032"><span class="h2">Other forms of lichen planus</span><span class="headingEndMark"> — </span>Other manifestations of lichen planus may be present in patients with cutaneous lesions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail lichen planus </strong>– When nails are involved, the disease spectrum varies from minor dystrophy to total nail loss  (<a class="graphic graphic_picture graphicRef80419 graphicRef85620 graphicRef85621 graphicRef86822" href="/z/d/graphic/80419.html" rel="external">picture 9A-D</a>). The disease process in lichen planus of the nails primarily occurs in the nail matrix. (See  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planopilaris </strong>–<strong> </strong>Lichen planopilaris is the term used to describe lichen planus that occurs on the scalp. Patients present with areas of hair loss with keratotic follicular papules that, left untreated, can progress to scarring alopecia  (<a class="graphic graphic_picture graphicRef52848" href="/z/d/graphic/52848.html" rel="external">picture 10</a>). Hair regrowth does not occur once follicles are destroyed. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral lichen planus </strong>–<strong> </strong>Lichen planus of the mucous membranes can occur in conjunction with cutaneous disease or independently. Mucous membrane disease may consist solely of lacelike Wickham's striae that are particularly evident on the buccal mucosa or can include papular, atrophic, or erosive lesions  (<a class="graphic graphic_picture graphicRef76338 graphicRef62826 graphicRef54143 graphicRef80848" href="/z/d/graphic/76338.html" rel="external">picture 11A-D</a>). Erosive mucous membrane disease is frequently painful and may lead to secondary complications including superficial candidal infection. Patients frequently report a persistent loss of appetite due to pain associated with eating. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital lichen planus </strong>–<strong> </strong>Genital lichen planus in men presents with violaceous papules on the glans penis  (<a class="graphic graphic_picture graphicRef60985 graphicRef76913" href="/z/d/graphic/60985.html" rel="external">picture 7B, 7D</a>), while in women lesions typically occur on the vulva. The vulvo-vaginal-gingival syndrome is an erosive form of lichen planus that involves the epithelium of the vulva, vestibule, vagina, and mouth; it is particularly resistant to treatment [<a href="#rid36">36,37</a>]. Although all three areas can be affected, the lesions may not be concurrent. The gingival epithelium is usually involved, but erosions, white plaques, or a whitish and lace-like reticular pattern may occur on the buccal mucosa, tongue, and palate  (<a class="graphic graphic_picture graphicRef72786" href="/z/d/graphic/72786.html" rel="external">picture 12</a>). (See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal lichen planus </strong>–<strong> </strong>Lichen planus may involve the esophagus, presenting with or without symptoms such as dysphagia or odynophagia [<a href="#rid38">38</a>]. Possible endoscopic findings include pseudomembranes, friable and inflamed mucosa, submucosal papules, lacy white plaques, erosions, strictures, and other abnormalities  (<a class="graphic graphic_picture graphicRef72940" href="/z/d/graphic/72940.html" rel="external">picture 13</a>). Concomitant oral, genital, or cutaneous lichen planus is frequently present [<a href="#rid38">38</a>]. The prevalence of esophageal lichen planus is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Otic lichen planus </strong>– The stratified squamous epithelia of the external auditory canals and tympanic membranes are potential sites for lichen planus. Common clinical features of otic lichen planus include erythema, induration, and stenosis of the external auditory canal; thickening of the tympanic membranes; otorrhea; and hearing loss [<a href="#rid39">39</a>]. Lichen planus of other body sites may or may not be present. Further study is necessary to determine the prevalence of this disease manifestation.</p><p></p><p class="headingAnchor" id="H511817"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Lichen planus is associated with a set of characteristic pathologic findings that are seen in cutaneous lichen planus and to a variable extent in lichen planus of other body sites. These include  (<a class="graphic graphic_picture graphicRef82025 graphicRef58826" href="/z/d/graphic/82025.html" rel="external">picture 14A-B</a>) [<a href="#rid40">40,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkeratosis without parakeratosis</p><p class="bulletIndent1"><span class="glyph">●</span>Vacuolization of the basal layer</p><p class="bulletIndent1"><span class="glyph">●</span>Civatte bodies (apoptotic keratinocytes) in the lower epidermis </p><p class="bulletIndent1"><span class="glyph">●</span>Wedge-shaped hypergranulosis, "saw-tooth" shaped rete ridges</p><p class="bulletIndent1"><span class="glyph">●</span>Small clefts at the dermal-epidermal junction (Max-Joseph spaces)</p><p class="bulletIndent1"><span class="glyph">●</span>Band-like, lymphocytic infiltrate at the dermal-epidermal junction</p><p class="bulletIndent1"><span class="glyph">●</span>Eosinophilic, colloid bodies (apoptotic keratinocytes) in the papillary dermis</p><p class="bulletIndent1"><span class="glyph">●</span>Pigment incontinence (most prominent in dark-skinned individuals)</p><p></p><p>The pathologic findings of lichen planus in other body sites and lichenoid drug eruptions are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis", section on 'Biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In many cases, the diagnosis of cutaneous lichen planus can be made based upon the recognition of consistent clinical findings. In cases in which the diagnosis is uncertain, a skin biopsy is useful for confirming the diagnosis. The diagnosis of the other forms of lichen planus is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H511809"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>The clinical evaluation of a patient with suspected cutaneous lichen planus consists of a patient interview and a physical examination. Patients should be questioned about medications (drugs that may induce lichen planus  (<a class="graphic graphic_table graphicRef83762" href="/z/d/graphic/83762.html" rel="external">table 1</a>)), pruritus (a common symptom of cutaneous lichen planus), oral or genital erosions or pain (findings suggestive of concomitant mucosal lichen planus), and dysphagia or odynophagia (findings suggestive of esophageal disease). We also typically inquire about risk factors for hepatitis C. (See <a class="local">'Additional testing'</a> below.)</p><p>The physical examination should include an examination of the entire cutaneous surface, including the scalp, as well as examination of the oral cavity and external genitalia. Performing a full examination aids in the assessment of the extent of cutaneous lesions and allows for the recognition of additional sites of involvement. </p><p class="headingAnchor" id="H511825"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A skin biopsy can be used to confirm a diagnosis of cutaneous lichen planus. A punch biopsy or shave biopsy that reaches the depth of the mid-dermis is usually sufficient. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Shave biopsy'</a>.)</p><p>Immunofluorescence studies are not routinely needed. Direct immunofluorescence may be performed in patients with bullous lesions to differentiate the condition from an autoimmune blistering disease. If performed, direct immunofluorescence often demonstrates colloid bodies in the papillary dermis that stain for complement and immunoglobulins (especially IgM) and irregular fibrin deposition along the dermal-epidermal junction [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H512326"><span class="h2">Dermoscopy</span><span class="headingEndMark"> — </span>Wickham's striae often can be visualized during dermoscopic examination of cutaneous lesions of lichen planus [<a href="#rid42">42-44</a>]. (See  <a class="medical medical_review" href="/z/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>.)</p><p class="headingAnchor" id="H3386667832"><span class="h1">ADDITIONAL TESTING</span><span class="headingEndMark"> — </span>Given the evidence that suggests an association between lichen planus and hepatitis C virus (HCV) infection, we routinely test for HCV infection in patients with lichen planus. However, there are conflicting opinions regarding the value of such testing, and there is disagreement on whether routine testing is essential in all locations. (See <a class="local">'Hepatitis C virus'</a> above and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Whom to test'</a>.)</p><p>In a United States study in which 195 patients with oral lichen planus were prospectively screened for liver abnormalities, no liver abnormalities or antibodies to hepatitis B or C were detected [<a href="#rid45">45</a>]. This report suggested that routine testing for HCV infection is not necessary. Others have suggested testing for HCV infection in patients diagnosed with lichen planus, particularly those with risk factors for HCV infection, due to the risks of morbidity and transmission that exist with HCV infection and the evidence suggesting an association between lichen planus and HCV [<a href="#rid9">9,10,46,47</a>].</p><p class="headingAnchor" id="H511832"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Key disorders in the differential diagnosis for classic presentations of cutaneous lichen planus include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichenoid drug eruption </strong>– Lichenoid drug eruptions (drug-induced lichen planus) should always be considered so that the offending agent can be withdrawn when possible  (<a class="graphic graphic_table graphicRef83762" href="/z/d/graphic/83762.html" rel="external">table 1</a>). The cutaneous manifestations closely resemble idiopathic lichen planus. The patient's history of drug exposure and a skin biopsy can aid in distinguishing lichenoid drug eruptions from idiopathic lichen planus. Lichenoid drug eruptions usually develop insidiously and can affect any area of the body surface  (<a class="graphic graphic_picture graphicRef80165 graphicRef59258 graphicRef83767 graphicRef83768" href="/z/d/graphic/80165.html" rel="external">picture 15A-D</a>). (See  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic graft-versus-host disease </strong>–<strong> </strong>Chronic graft-versus-host disease can produce a lichenoid eruption with clinical and histologic findings similar to lichen planus. The history of preceding hematopoietic cell transplant is helpful for diagnosis. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Mucocutaneous'</a>.)</p><p></p><p>Other papulosquamous and dermatitic disorders, such as psoriasis, atopic dermatitis, lichen simplex chronicus, subacute cutaneous lupus erythematosus, discoid lupus erythematosus, pityriasis rosea, secondary syphilis, and prurigo nodularis can usually be distinguished from lichen planus through a careful evaluation for clinical findings that are more consistent with these disorders. Lesions suspicious for bullous lichen planus should be distinguished from autoimmune blistering diseases through a biopsy and immunofluorescence studies. Of note, skin involvement in paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PAMS) often presents as lichenoid skin lesions. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Diagnostic tests'</a> and  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The natural history of most cases of cutaneous lichen planus is to remit within one to two years [<a href="#rid48">48</a>]. Oral, genital, scalp, and nail lichen planus tend to be more persistent. The clinical course of these types of lichen planus and lichenoid drug eruptions are viewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">"Oral lichen planus: Management and prognosis", section on 'Prognosis and follow-up'</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Natural history'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Clinical course'</a> and  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Clinical course'</a>.)</p><p class="headingAnchor" id="H714266"><span class="h2">Comorbid disease</span><span class="headingEndMark"> — </span>The results of two case-control studies suggest that the prevalence of dyslipidemia may be greater among patients with lichen planus than among individuals without this disease [<a href="#rid49">49,50</a>]. Additional studies are necessary to confirm an association between dyslipidemia and lichen planus and to explore the clinical relevance of this finding. Further study is also necessary to clarify whether there is an association between oral lichen planus and thyroid disease [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are few data to support evidence-based recommendations for the treatment of lichen planus [<a href="#rid53">53-55</a>]. Only a few randomized trials have been performed, most of which were small and subject to methodologic error [<a href="#rid56">56</a>]. </p><p>The treatment of cutaneous lichen planus is reviewed below. Detailed information on the management of other forms of lichen planus can be found separately. (See  <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">"Oral lichen planus: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Cutaneous lichen planus</span><span class="headingEndMark"> — </span>Cutaneous lichen planus usually is a self-limited disorder. Thus, treatment is focused on accelerating resolution and managing pruritus [<a href="#rid1">1</a>]. (See <a class="local">'Natural history'</a> above.)</p><p class="headingAnchor" id="H511953"><span class="h3">First-line therapy</span><span class="headingEndMark"> — </span>Topical corticosteroids are commonly used as first-line treatment for localized cutaneous lichen planus. For patients with generalized disease, in whom monotherapy with topical corticosteroids is less practical, topical corticosteroids are often used as an adjunct to systemic therapy or phototherapy. (See <a class="local">'Second-line therapy'</a> below.)</p><p class="headingAnchor" id="H511961"><span class="h4">Topical corticosteroids</span><span class="headingEndMark"> — </span>Although topical corticosteroids are the mainstay of treatment for patients with localized cutaneous lichen planus, the efficacy of these agents has not been evaluated in clinical studies. Recommendations based upon clinical experience and the relative safety of this mode of treatment support the use of topical corticosteroids as first-line therapy [<a href="#rid1">1,5</a>]. </p><p>We typically treat localized cutaneous lichen planus on the trunk and extremities with a high-potency or super high-potency topical corticosteroid (eg, 0.05% <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate, 0.05% <a class="drug drug_general" data-topicid="9356" href="/z/d/drug information/9356.html" rel="external">diflorasone</a> diacetate) cream or ointment twice daily  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>). Because topical corticosteroid-induced cutaneous atrophy is most likely to occur in intertriginous or facial skin, we prefer to use mid-potency or low-potency corticosteroid creams or ointments when treating these areas. Efficacy should be assessed after two to three weeks.</p><p>Patients should be cautioned about the risk for cutaneous atrophy and should be followed closely for this side effect. The adverse effects of topical corticosteroid therapy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects"</a>.)</p><p class="headingAnchor" id="H511969"><span class="h4">Intralesional corticosteroids</span><span class="headingEndMark"> — </span>The thick lesions of hypertrophic lichen planus may be less likely than classic cutaneous lesions to respond well to a topical corticosteroid. Clinical experience suggests that intralesional corticosteroid therapy can be beneficial for the treatment of hypertrophic lichen planus [<a href="#rid5">5</a>]. </p><p>We typically administer <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide in a concentration of 2.5 to 10 mg/mL. The quantity administered should blanch or at least infiltrate hypertrophic lesions. Extension of the corticosteroid into the surrounding normal skin should be minimized. We limit the total dose of triamcinolone to no more than 40 mg per treatment session. Injections may be repeated after four to six weeks.</p><p>Cutaneous atrophy and hypopigmentation may occur as a result of intralesional corticosteroid therapy. Side effects of this treatment are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p class="headingAnchor" id="H511977"><span class="h3">Second-line therapy</span><span class="headingEndMark"> — </span>Patients with cutaneous lichen planus who cannot be treated adequately with local corticosteroids (eg, generalized disease or local corticosteroid-refractory disease) may benefit from other treatments, such as oral glucocorticoids, phototherapy, and oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>. Only acitretin has been evaluated in a blinded placebo-controlled randomized trial. The limited availability of data and the potential for lichen planus to spontaneously resolve contributes to uncertainty about the efficacy of treatments. The risks and benefits of treatment should be considered carefully prior to treatment.</p><p class="headingAnchor" id="H511985"><span class="h4">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Oral glucocorticoid therapy may be beneficial for cutaneous lichen planus based upon clinical experience and a few small uncontrolled studies in which improvements in the signs or symptoms of cutaneous lichen planus occurred during oral glucocorticoid therapy [<a href="#rid53">53,57,58</a>]. We consider prescribing a short course of an oral glucocorticoid when acute control of cutaneous lichen planus is necessary for patients with extensive disease. Continued, long-term treatment with systemic glucocorticoids is less favorable due to the serious side effects associated with long-term therapy. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>The optimal dose and duration of systemic glucocorticoid therapy is not known. Our preference is to begin with 30 to 60 mg daily for four to six weeks followed by a taper of the dose to discontinuation over the next four to six weeks. Lower doses and shorter courses have also been proposed in the literature [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H512347"><span class="h4">Phototherapy</span><span class="headingEndMark"> — </span>Ultraviolet B (UVB) and psoralen plus ultraviolet A (PUVA) phototherapy are utilized for the treatment of cutaneous lichen planus. Narrowband UVB is the most common modality used [<a href="#rid3">3,5</a>]. Similar to other treatments for cutaneous lichen planus, data on the efficacy of phototherapy are limited. Placebo-controlled randomized trials have not been performed. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p>Non-placebo-controlled studies evaluating narrowband UVB for cutaneous lichen planus have generally yielded favorable findings. A small, unblinded, randomized trial of 46 patients with generalized lichen planus that compared treatment with narrowband UVB (three times per week for six weeks) to oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.3 mg/kg per day for six weeks) found a significantly better response in the patients who received phototherapy [<a href="#rid59">59</a>]. Complete responses were attained by 12 of 23 patients in the phototherapy group (52 percent) versus 3 of 23 patients in the prednisone group (13 percent). </p><p>Several other studies suggest benefit of UVB phototherapy [<a href="#rid60">60-64</a>]. As an example, a prospective uncontrolled study of 16 patients with generalized cutaneous lichen planus found that 11 patients achieved at least a 90 percent reduction in papules after treatment with narrowband UVB (three times weekly for 40 sessions). Itching tended to improve early in the course of therapy. Additionally, a retrospective study in which 50 patients with generalized cutaneous lichen planus were treated with either narrowband UVB (n = 43) or broadband UVB (n = 7) three times per week found documentation of complete remissions in 70 percent of patients [<a href="#rid61">61</a>]. Among those who achieved a complete remission, 85 percent remained in remission after a median follow-up period of 34.7 months.</p><p>PUVA photochemotherapy, which requires oral or bath administration of 8-methoxypsoralen, also seems to be efficacious for some patients with cutaneous lichen planus based upon retrospective studies and case series [<a href="#rid65">65-70</a>]. Although the findings of a retrospective analysis of 28 patients with generalized lichen planus raised the question of whether PUVA is more likely than narrowband UVB to induce an initial response [<a href="#rid65">65</a>], the study failed to find a significant difference in the long term benefit of these treatments. Additional studies are needed to explore the comparative efficacy of PUVA and narrowband UVB phototherapy. </p><p>Given the lack of data confirming superiority of a particular mode of phototherapy, narrowband UVB therapy (initially given three times per week) is our preferred mode of phototherapy for cutaneous lichen planus due to the ease with which this treatment can be administered. In contrast to narrowband UVB, PUVA requires administration of an oral or topical photosensitizer. Additionally, oral PUVA requires a period of ocular photoprotection following treatment. We taper the frequency of narrowband UVB treatment once an adequate response is achieved. If no response is observed after three to four months, we discontinue treatment.</p><p>Burning, blistering, and pruritus are potential side effects of phototherapy. Short- and long-term side effects of phototherapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)", section on 'Short- and long-term adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H511993"><span class="h4">Oral retinoids</span><span class="headingEndMark"> — </span>The best support for the use of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, an oral retinoid, for lichen planus stems from a placebo-controlled randomized trial of 65 patients with cutaneous lichen planus [<a href="#rid71">71,72</a>]. At the end of eight weeks, patients treated with 30 mg per day of acitretin (n = 32) were significantly more likely to have achieved remission or marked improvement than the 33 patients in the placebo group (64 versus 13 percent achieved this level of response). Improvement during treatment with acitretin and other oral retinoids has also been documented in small, open-label studies or case reports [<a href="#rid73">73-75</a>]. </p><p>Although the randomized trial strongly supports a beneficial effect of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> on cutaneous lichen planus, the potential adverse effects of acitretin account for our categorization of acitretin as a second-line treatment rather than a first-line treatment for cutaneous lichen planus. Xerosis, hair loss, hypertriglyceridemia, visual changes, myalgias, pseudotumor cerebri, and skeletal abnormalities are some examples of retinoid side effects. We primarily reserve the use of acitretin for patients with disease that cannot be managed with local corticosteroids or phototherapy.</p><p>Oral retinoids should be administered by or in consultation with clinicians familiar with the use and side effects of this therapy (eg, a dermatologist). <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is teratogenic, and is contraindicated for women who are pregnant or intend to become pregnant. Pregnancy is contraindicated for three years after discontinuation of acitretin. </p><p class="headingAnchor" id="H1178449"><span class="h3">Other treatments</span><span class="headingEndMark"> — </span>Oral antihistamines (eg, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> hydrochloride 10 to 50 mg four times a day, as necessary) may be helpful in controlling pruritus. Other medications that have been reported to be of benefit in some patients with cutaneous lichen planus include <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid56">56</a>], <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid76">76,77</a>], low molecular weight heparin [<a href="#rid78">78,79</a>], <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> [<a href="#rid80">80</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid53">53</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid4">4,81</a>], <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> [<a href="#rid82">82</a>], <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid83">83,84</a>], and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid85">85</a>]. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil has been used successfully in the treatment of at least two patients with extensive generalized lichen planus and one patient with resistant hypertrophic and bullous lichen planus [<a href="#rid86">86,87</a>]. Further study is necessary to confirm the efficacy of all of these agents.</p><p>The results of a small uncontrolled study suggest that <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, a phosphodiesterase inhibitor, may be beneficial for lichen planus [<a href="#rid88">88</a>]. Treatment with apremilast (20 mg twice daily for 12 weeks) was associated with clinical improvement in all 10 patients, including three patients who achieved at least a two-grade improvement in the physician global assessment score. Additional studies are necessary to explore the efficacy and safety of apremilast for lichen planus. </p><p>The role of tumor necrosis factor (TNF)-alpha inhibitors in the treatment of lichen planus is unclear. Reports of both exacerbation and improvement of lichen planus or lichen planus-like eruptions with TNF-alpha inhibitor therapy exist [<a href="#rid89">89-92</a>].</p><p class="headingAnchor" id="H79796085"><span class="h2">Other types of lichen planus</span></p><p class="headingAnchor" id="H12"><span class="h3">Genital lichen planus</span><span class="headingEndMark"> — </span>Topical corticosteroids or topical calcineurin inhibitors are often used in the treatment of genital lichen planus. The treatment of vulvar lichen planus is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Lichen planopilaris</span><span class="headingEndMark"> — </span>The treatment of lichen planopilaris (LPP) can be difficult. Topical corticosteroids or intralesional corticosteroids are often used as first-line therapies  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>) [<a href="#rid93">93-96</a>]. The treatment of LPP is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H259780496"><span class="h3">Oral lichen planus</span><span class="headingEndMark"> — </span>Topical corticosteroids are first-line therapy for oral lichen planus. The treatment of oral lichen planus is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">"Oral lichen planus: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H174264512"><span class="h3">Nail lichen planus</span><span class="headingEndMark"> — </span>The treatment of lichen planus involving the nails is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Lichen planus'</a>.)</p><p class="headingAnchor" id="H1023071"><span class="h3">Lichenoid drug eruption</span><span class="headingEndMark"> — </span>The management of drug-induced lichen planus is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H3922962417"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118792.html" rel="external">"Society guideline links: Lichen planus"</a>.)</p><p class="headingAnchor" id="H371672654"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87110.html" rel="external">"Patient education: Lichen planus (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Lichen planus is a mucocutaneous disorder that most commonly affects middle-aged adults. (See <a class="local">'Introduction'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential contributors </strong>– Clinicians should be aware of the potential for drug-induced forms of lichen planus. Studies have also suggested an association of lichen planus with hepatitis C virus (HCV), although the strength of this association varies geographically. Further studies are necessary to determine if HCV screening should be performed in patients with lichen planus. (See <a class="local">'Hepatitis C virus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Lichen planus may affect the skin, nails, or mucous membranes (see <a class="local">'Clinical features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous lichen planus </strong>– Cutaneous lichen planus typically presents as pruritic, polygonal, violaceous papules and/or plaques with an overlying white, lacelike pattern (Wickham's striae)  (<a class="graphic graphic_picture graphicRef63590 graphicRef76383 graphicRef50579 graphicRef53839" href="/z/d/graphic/63590.html" rel="external">picture 1A-D</a>). Significant post-inflammatory hyperpigmentation is common. Cutaneous lichen planus may also present with hypertrophic or vesicobullous lesions. (See <a class="local">'Cutaneous lichen planus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lichen planopilaris </strong>– Lichen planopilaris is a form of lichen planus that affects the scalp and can lead to scarring alopecia. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral and genital lichen planus </strong>– When lichen planus involves the oral cavity, it may present with only lacelike Wickham's striae or may include papular, atrophic, or erosive lesions. Genital areas can also be affected by lichen planus. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history </strong>– Cutaneous lichen planus often spontaneously resolves after one to two years. Oral, genital, scalp, and nail lichen planus tend to be more chronic. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Localized disease </strong>– We suggest high-potency or super high-potency topical corticosteroids as initial treatment of localized cutaneous lichen planus on the trunk or extremities based upon clinical experience and the relative safety of this therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Intralesional corticosteroids can be useful in patients with hypertrophic lichen planus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive disease </strong>– Patients with widespread cutaneous disease may benefit from phototherapy, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, or a short course of systemic glucocorticoid therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H131867345"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Fuad Muakkassa for his contributions to this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med 2012; 366:723.</a></li><li><a class="nounderline abstract_t">Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. J Dtsch Dermatol Ges 2013; 11:309.</a></li><li><a class="nounderline abstract_t">Schwager Z, Stern M, Cohen J, Femia A. Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers. J Am Acad Dermatol 2019; 81:1397.</a></li><li><a class="nounderline abstract_t">Pandhi D, Singal A, Bhattacharya SN. Lichen planus in childhood: a series of 316 patients. Pediatr Dermatol 2014; 31:59.</a></li><li><a class="nounderline abstract_t">Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol 2009; 48:682.</a></li><li><a class="nounderline abstract_t">Hussein MR. Evaluation of angiogenesis in normal and lichen planus skin by CD34 protein immunohistochemistry: preliminary findings. Cell Biol Int 2007; 31:1292.</a></li><li><a class="nounderline abstract_t">Chen X, Liu Z, Yue Q. The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication. J Huazhong Univ Sci Technolog Med Sci 2007; 27:739.</a></li><li><a class="nounderline abstract_t">Rhodus NL, Cheng B, Ondrey F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm 2007; 2007:19854.</a></li><li><a class="nounderline abstract_t">Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 2009; 145:1040.</a></li><li><a class="nounderline abstract_t">Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004; 151:1172.</a></li><li><a class="nounderline abstract_t">Chainani-Wu N, Lozada-Nur F, Terrault N. Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:171.</a></li><li><a class="nounderline abstract_t">Campisi G, Di Fede O, Craxi A, et al. Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity. J Am Acad Dermatol 2004; 51:364.</a></li><li><a class="nounderline abstract_t">Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermüller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104:903.</a></li><li><a class="nounderline abstract_t">Wickham LF. Sur un signe pathognomonique de Lichen du Wilson (lichen plan) tries et ponctuations grisatres. Ann Dermatol Syphiligr (Paris) 1895; 6:517.</a></li><li><a class="nounderline abstract_t">Ber Rahman S, Ul Bari A, Mumtaz N. Unilateral Blaschkoid lichen planus involving the entire half of the body, a unique presentation. Dermatol Online J 2007; 13:36.</a></li><li><a class="nounderline abstract_t">Klein HA, Krathen RA, Hsu S. Widespread Blaschkoid lichen planus. Dermatol Online J 2006; 12:17.</a></li><li><a class="nounderline abstract_t">Akarsu S, Ilknur T, Özer E, Fetil E. Lichen planus pigmentosus distributed along the lines of Blaschko. Int J Dermatol 2013; 52:253.</a></li><li><a class="nounderline abstract_t">Möhrenschlager M, Engst R, Hein R, Ring J. Primary manifestation of a zosteriform lichen planus: isotopic response following herpes zoster sine herpete? Br J Dermatol 2008; 158:1145.</a></li><li><a class="nounderline abstract_t">Perry D, Fazel N. Zosteriform lichen planus. Dermatol Online J 2006; 12:3.</a></li><li><a class="nounderline abstract_t">Shemer A, Weiss G, Trau H. Wolf's isotopic response: a case of zosteriform lichen planus on the site of healed herpes zoster. J Eur Acad Dermatol Venereol 2001; 15:445.</a></li><li><a class="nounderline abstract_t">Ghorpade A. Wolf's isotopic response--lichen planus at the site of healed herpes zoster in an Indian woman. Int J Dermatol 2010; 49:234.</a></li><li><a class="nounderline abstract_t">Manz B, Paasch U, Sticherling M. Squamous cell carcinoma as a complication of long-standing hypertrophic lichen planus. Int J Dermatol 2005; 44:773.</a></li><li><a class="nounderline abstract_t">Reich HL, Nguyen JT, James WD. Annular lichen planus: a case series of 20 patients. J Am Acad Dermatol 2004; 50:595.</a></li><li><a class="nounderline abstract_t">Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol 2010; 24:535.</a></li><li><a class="nounderline abstract_t">Kashima A, Tajiri A, Yamashita A, et al. Two Japanese cases of lichen planus pigmentosus-inversus. Int J Dermatol 2007; 46:740.</a></li><li><a class="nounderline abstract_t">Li B, Li JH, Xiao T, et al. Annular atrophic lichen planus. Eur J Dermatol 2010; 20:842.</a></li><li><a class="nounderline abstract_t">Friedman DB, Hashimoto K. Annular atrophic lichen planus. J Am Acad Dermatol 1991; 25:392.</a></li><li><a class="nounderline abstract_t">Morales-Callaghan A Jr, Martínez G, Aragoneses H, Miranda-Romero A. Annular atrophic lichen planus. J Am Acad Dermatol 2005; 52:906.</a></li><li><a class="nounderline abstract_t">Al-Khenaizan S, Al Mubarak L. Ulcerative lichen planus of the sole: excellent response to topical tacrolimus. Int J Dermatol 2008; 47:626.</a></li><li><a class="nounderline abstract_t">Henderson RL Jr, Williford PM, Molnar JA. Cutaneous ulcerative lichen planus exhibiting pathergy, response to acitretin. J Drugs Dermatol 2004; 3:191.</a></li><li><a class="nounderline abstract_t">Sánchez-Pérez J, Rios Buceta L, Fraga J, García-Díez A. Lichen planus with lesions on the palms and/or soles: prevalence and clinicopathological study of 36 patients. Br J Dermatol 2000; 142:310.</a></li><li><a class="nounderline abstract_t">Gutte R, Khopkar U. Perforating lichen planus. Indian J Dermatol Venereol Leprol 2011; 77:515.</a></li><li><a class="nounderline abstract_t">Hanau D, Sengel D. Perforating lichen planus. J Cutan Pathol 1984; 11:176.</a></li><li><a class="nounderline abstract_t">Zaraa I, Mahfoudh A, Sellami MK, et al. Lichen planus pemphigoides: four new cases and a review of the literature. Int J Dermatol 2013; 52:406.</a></li><li><a class="nounderline abstract_t">Kim H, Pomeranz MK. Lupus erythematosus and lichen planus overlap syndrome. J Drugs Dermatol 2004; 3:311.</a></li><li><a class="nounderline abstract_t">Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. Int J Dermatol 1989; 28:381.</a></li><li><a class="nounderline abstract_t">Eisen D. The vulvovaginal-gingival syndrome of lichen planus. The clinical characteristics of 22 patients. Arch Dermatol 1994; 130:1379.</a></li><li><a class="nounderline abstract_t">Fox LP, Lightdale CJ, Grossman ME. Lichen planus of the esophagus: what dermatologists need to know. J Am Acad Dermatol 2011; 65:175.</a></li><li><a class="nounderline abstract_t">Sartori-Valinotti JC, Bruce AJ, Krotova Khan Y, Beatty CW. A 10-year review of otic lichen planus: the Mayo Clinic experience. JAMA Dermatol 2013; 149:1082.</a></li><li class="breakAll">Weedon D. The lichenoid reaction pattern (interface dermatitis). In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.35.</li><li class="breakAll">Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Lever's Histopathology of the Skin, 10th ed, Elder DE (Ed), Lippincott Williams &amp; Wilkins, 2009. p.169.</li><li><a class="nounderline abstract_t">Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol 2012; 166:1198.</a></li><li><a class="nounderline abstract_t">Friedman P, Sabban EC, Marcucci C, et al. Dermoscopic findings in different clinical variants of lichen planus. Is dermoscopy useful? Dermatol Pract Concept 2015; 5:51.</a></li><li><a class="nounderline abstract_t">Ankad BS, Beergouder SL. Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. Dermatol Pract Concept 2016; 6:9.</a></li><li><a class="nounderline abstract_t">Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46:207.</a></li><li><a class="nounderline abstract_t">Gimenez-García R, Pérez-Castrillón JL. Lichen planus and hepatitis C virus infection. J Eur Acad Dermatol Venereol 2003; 17:291.</a></li><li><a class="nounderline abstract_t">Lapane KL, Jakiche AF, Sugano D, et al. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998; 93:591.</a></li><li><a class="nounderline abstract_t">Irvine C, Irvine F, Champion RH. Long-term follow-up of lichen planus. Acta Derm Venereol 1991; 71:242.</a></li><li><a class="nounderline abstract_t">Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J, et al. Cardiovascular risk factors in patients with lichen planus. Am J Med 2011; 124:543.</a></li><li><a class="nounderline abstract_t">Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol 2009; 161:626.</a></li><li><a class="nounderline abstract_t">Siponen M, Huuskonen L, Läärä E, Salo T. Association of oral lichen planus with thyroid disease in a Finnish population: a retrospective case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:319.</a></li><li><a class="nounderline abstract_t">Lo Muzio L, Santarelli A, Campisi G, et al. Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found. Clin Oral Investig 2013; 17:333.</a></li><li><a class="nounderline abstract_t">Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.</a></li><li><a class="nounderline abstract_t">Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.</a></li><li><a class="nounderline abstract_t">Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; :CD008092.</a></li><li><a class="nounderline abstract_t">Atzmony L, Reiter O, Hodak E, et al. Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2016; 17:11.</a></li><li><a class="nounderline abstract_t">Verma KK, Mittal R, Manchanda Y. Lichen planus treated with betamethasone oral mini-pulse therapy. Indian J Dermatol Venereol Leprol 2000; 66:34.</a></li><li><a class="nounderline abstract_t">Ramesh M, Balachandran C, Shenoi SD, Rai VM. Efficacy of steroid oral mini-pulse therapy in lichen planus: an open trial in 35 patients. Indian J Dermatol Venereol Leprol 2006; 72:156.</a></li><li><a class="nounderline abstract_t">Iraji F, Faghihi G, Asilian A, et al. Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial. J Res Med Sci 2011; 16:1578.</a></li><li><a class="nounderline abstract_t">Gamil H, Nassar A, Saadawi A, et al. Narrow-band ultraviolet B phototherapy in lichen planus. J Eur Acad Dermatol Venereol 2009; 23:589.</a></li><li><a class="nounderline abstract_t">Pavlotsky F, Nathansohn N, Kriger G, et al. Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients. Photodermatol Photoimmunol Photomed 2008; 24:83.</a></li><li><a class="nounderline abstract_t">Saricaoğlu H, Karadogan SK, Başkan EB, Tunali S. Narrowband UVB therapy in the treatment of lichen planus. Photodermatol Photoimmunol Photomed 2003; 19:265.</a></li><li><a class="nounderline abstract_t">Taneja A, Taylor CR. Narrow-band UVB for lichen planus treatment. Int J Dermatol 2002; 41:282.</a></li><li><a class="nounderline abstract_t">Habib F, Stoebner PE, Picot E, et al. [Narrow band UVB phototherapy in the treatment of widespread lichen planus]. Ann Dermatol Venereol 2005; 132:17.</a></li><li><a class="nounderline abstract_t">Wackernagel A, Legat FJ, Hofer A, et al. Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus. Photodermatol Photoimmunol Photomed 2007; 23:15.</a></li><li><a class="nounderline abstract_t">Ortonne JP, Thivolet J, Sannwald C. Oral photochemotherapy in the treatment of lichen planus (LP). Clinical results, histological and ultrastructural observations. Br J Dermatol 1978; 99:77.</a></li><li><a class="nounderline abstract_t">Gonzalez E, Momtaz-T K, Freedman S. Bilateral comparison of generalized lichen planus treated with psoralens and ultraviolet A. J Am Acad Dermatol 1984; 10:958.</a></li><li><a class="nounderline abstract_t">Kerscher M, Volkenandt M, Lehmann P, et al. PUVA-bath photochemotherapy of lichen planus. Arch Dermatol 1995; 131:1210.</a></li><li><a class="nounderline abstract_t">Helander I, Jansén CT, Meurman L. Long-term efficacy of PUVA treatment in lichen planus: comparison of oral and external methoxsalen regimens. Photodermatol 1987; 4:265.</a></li><li><a class="nounderline abstract_t">Karvonen J, Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl (Stockh) 1985; 120:53.</a></li><li><a class="nounderline abstract_t">Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991; 24:434.</a></li><li><a class="nounderline abstract_t">Alamri A, Alsenaid A, Ruzicka T, Wolf R. Hypertrophic lichen planus - successful treatment with acitretin. Dermatol Ther 2016; 29:173.</a></li><li><a class="nounderline abstract_t">Ott F, Bollag W, Geiger JM. Efficacy of oral low-dose tretinoin (all-trans-retinoic acid) in lichen planus. Dermatology 1996; 192:334.</a></li><li><a class="nounderline abstract_t">Viglioglia PA, Villanueva CR, Martorano AD, et al. Efficacy of acitretin in severe cutaneous lichen planus. J Am Acad Dermatol 1990; 22:852.</a></li><li><a class="nounderline abstract_t">Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985; 35:385.</a></li><li><a class="nounderline abstract_t">Moura AK, Moure ER, Romiti R. Treatment of cutaneous lichen planus with thalidomide. Clin Exp Dermatol 2009; 34:101.</a></li><li><a class="nounderline abstract_t">Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7:769.</a></li><li><a class="nounderline abstract_t">Stefanidou MP, Ioannidou DJ, Panayiotides JG, Tosca AD. Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999; 141:1040.</a></li><li><a class="nounderline abstract_t">Akdeniz S, Harman M, Atmaca S, Yaldiz M. The management of lichen planus with low-molecular-weight heparin (enoxaparin). Int J Clin Pract 2005; 59:1268.</a></li><li><a class="nounderline abstract_t">Sehgal VN, Abraham GJ, Malik GB. Griseofulvin therapy in lichen planus. A double-blind controlled trial. Br J Dermatol 1972; 87:383.</a></li><li><a class="nounderline abstract_t">Başak PY, Başak K. Generalized lichen planus in childhood: is dapsone an effective treatment modality? Turk J Pediatr 2002; 44:346.</a></li><li><a class="nounderline abstract_t">Bauzá A, España A, Gil P, et al. Successful treatment of lichen planus with sulfasalazine in 20 patients. Int J Dermatol 2005; 44:158.</a></li><li><a class="nounderline abstract_t">Rasi A, Behzadi AH, Davoudi S, et al. Efficacy of oral metronidazole in treatment of cutaneous and mucosal lichen planus. J Drugs Dermatol 2010; 9:1186.</a></li><li><a class="nounderline abstract_t">Büyük AY, Kavala M. Oral metronidazole treatment of lichen planus. J Am Acad Dermatol 2000; 43:260.</a></li><li><a class="nounderline abstract_t">Ramírez P, Feito M, Sendagorta E, et al. Childhood actinic lichen planus: successful treatment with antimalarials. Australas J Dermatol 2012; 53:e10.</a></li><li><a class="nounderline abstract_t">Frieling U, Bonsmann G, Schwarz T, et al. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol 2003; 49:1063.</a></li><li><a class="nounderline abstract_t">Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol 1999; 135:1420.</a></li><li><a class="nounderline abstract_t">Paul J, Foss CE, Hirano SA, et al. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. J Am Acad Dermatol 2013; 68:255.</a></li><li><a class="nounderline abstract_t">Alam MS, LaBelle B. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. JAAD Case Rep 2020; 6:219.</a></li><li><a class="nounderline abstract_t">Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.</a></li><li><a class="nounderline abstract_t">Niebel D, Wilsmann-Theis D, Wenzel J. Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. J Dermatol 2020; 47:397.</a></li><li><a class="nounderline abstract_t">Holló P, Szakonyi J, Kiss D, et al. Successful treatment of lichen planus with adalimumab. Acta Derm Venereol 2012; 92:385.</a></li><li><a class="nounderline abstract_t">Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol 2007; 57:47.</a></li><li><a class="nounderline abstract_t">Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg 2009; 28:3.</a></li><li><a class="nounderline abstract_t">Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris: some progress, but a long way to go. J Am Acad Dermatol 2010; 62:398.</a></li><li><a class="nounderline abstract_t">Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol 2005; 53:1.</a></li></ol></div><div id="topicVersionRevision">Topic 5662 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356325" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23320493" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical variants of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31004729" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23627802" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lichen planus in childhood: a series of 316 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570072" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524679" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evaluation of angiogenesis in normal and lichen planus skin by CD34 protein immunohistochemistry: preliminary findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231758" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17497029" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770446" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606512" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316544" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatitis C virus and lichen planus: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337978" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440441" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sur un signe pathognomonique de Lichen du Wilson (lichen plan) tries et ponctuations grisatres</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328230" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unilateral Blaschkoid lichen planus involving the entire half of the body, a unique presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459303" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Widespread Blaschkoid lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349081" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lichen planus pigmentosus distributed along the lines of Blaschko.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284381" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary manifestation of a zosteriform lichen planus: isotopic response following herpes zoster sine herpete?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16962018" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Zosteriform lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11763387" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Wolf's isotopic response: a case of zosteriform lichen planus on the site of healed herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Wolf's isotopic response--lichen planus at the site of healed herpes zoster in an Indian woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135151" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Squamous cell carcinoma as a complication of long-standing hypertrophic lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034510" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Annular lichen planus: a case series of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840200" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614807" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two Japanese cases of lichen planus pigmentosus-inversus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822974" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Annular atrophic lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894780" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Annular atrophic lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858488" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Annular atrophic lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477162" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ulcerative lichen planus of the sole: excellent response to topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15098977" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cutaneous ulcerative lichen planus exhibiting pathergy, response to acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10730766" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lichen planus with lesions on the palms and/or soles: prevalence and clinicopathological study of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21727704" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Perforating lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6207217" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perforating lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331194" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lichen planus pemphigoides: four new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15176168" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lupus erythematosus and lichen planus overlap syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2767837" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979437" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The vulvovaginal-gingival syndrome of lichen planus. The clinical characteristics of 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536343" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lichen planus of the esophagus: what dermatologists need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824252" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A 10-year review of otic lichen planus: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824252" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A 10-year review of otic lichen planus: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824252" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A 10-year review of otic lichen planus: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22296226" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26693092" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dermoscopic findings in different clinical variants of lichen planus. Is dermoscopy useful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222766" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807431" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702068" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lichen planus and hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576453" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1678229" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term follow-up of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605731" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiovascular risk factors in patients with lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438850" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Lichen planus and dyslipidaemia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656530" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Association of oral lichen planus with thyroid disease in a Finnish population: a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22699661" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875189" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of lichen planus. An evidence-based medicine analysis of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735381" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interventions for treating oral lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336835" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Interventions for erosive lichen planus affecting mucosal sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26507510" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20877018" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lichen planus treated with betamethasone oral mini-pulse therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707830" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of steroid oral mini-pulse therapy in lichen planus: an open trial in 35 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22973366" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771445" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Narrow-band ultraviolet B phototherapy in lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353088" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14535898" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Narrowband UVB therapy in the treatment of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100704" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Narrow-band UVB for lichen planus treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746601" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : [Narrow band UVB phototherapy in the treatment of widespread lichen planus].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254030" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/678468" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Oral photochemotherapy in the treatment of lichen planus (LP). Clinical results, histological and ultrastructural observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736339" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bilateral comparison of generalized lichen planus treated with psoralens and ultraviolet A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574847" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : PUVA-bath photochemotherapy of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3697349" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term efficacy of PUVA treatment in lichen planus: comparison of oral and external methoxsalen regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3869416" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1829465" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809380" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hypertrophic lichen planus - successful treatment with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8864368" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy of oral low-dose tretinoin (all-trans-retinoic acid) in lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140841" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of acitretin in severe cutaneous lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3858060" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Systemic isotretinoin treatment of oral and cutaneous lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076811" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of cutaneous lichen planus with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720694" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A case series of 48 patients treated with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606849" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236078" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The management of lichen planus with low-molecular-weight heparin (enoxaparin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4562169" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Griseofulvin therapy in lichen planus. A double-blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12458814" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Generalized lichen planus in childhood: is dapsone an effective treatment modality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689219" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Successful treatment of lichen planus with sulfasalazine in 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941941" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy of oral metronidazole in treatment of cutaneous and mucosal lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906648" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Oral metronidazole treatment of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309344" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Childhood actinic lichen planus: successful treatment with antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639385" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of severe lichen planus with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566854" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22910104" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32123715" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539844" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31907939" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101904" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful treatment of lichen planus with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467854" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341936" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lichen planopilaris: update on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061055" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Commentary: treatment of lichen planopilaris: some progress, but a long way to go.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965418" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Update on primary cicatricial alopecias.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
